How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

224 results for

Eslicarbazepine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia

Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Eslicarbazepine Acetate as Therapy (...) - Portela C S.A. Study Details Study Description Go to Brief Summary: The primary objective of this study is to assess the efficacy of Eslicarbazepine acetate (ESL) as therapy in subjects with Post-herpetic Neuralgia (PHN) over a 15 week treatment phase. Condition or disease Intervention/treatment Phase Post Herpetic Neuralgia Drug: Eslicarbazepine acetate (BIA 2-093) Drug: Placebo Phase 3 Detailed Description: Post-herpetic neuralgia (PHN) is a syndrome of intractable pain following an acute infection

2010 Clinical Trials

102. Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures

Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01162460 Recruitment Status : Completed First

2010 Clinical Trials

103. Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain

Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Eslicarbazepine Acetate (...) ): Bial - Portela C S.A. Study Details Study Description Go to Brief Summary: The primary objective of this study is to assess the efficacy of Eslicarbazepine acetate (ESL) as therapy in subjects with Diabetic Neuropathic Pain (DNP) over a 15 week treatment phase. Condition or disease Intervention/treatment Phase Painful Diabetic Neuropathy Drug: Eslicarbazepine acetate (BIA 2-093) Drug: Placebo Phase 3 Detailed Description: Diabetic neuropathic pain (DNP) is one of the most common complications

2010 Clinical Trials

104. Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01091662 Recruitment Status

2010 Clinical Trials

105. Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. (Abstract)

Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. Combination therapy is frequently required in the management of epilepsy. The primary objective of this study was to investigate the pharmacokinetic interaction between eslicarbazepine acetate (ESL) 1200 mg once daily and topiramate (TPM) 200 mg once daily in healthy subjects.Multiple-dose, open-label, one-sequence study in two parallel groups of 16 healthy male volunteers. After an 8-day (...) treatment with ESL (Group A) or TPM (Group B), ESL and TPM were co-administered for 19 days. A bioequivalence approach based on a within-subject comparison was used to investigate a potential drug-drug interaction. End/start of treatment geometric mean ratios (GMR, %) and 90% confidence intervals (90% CI) were calculated for maximum plasma concentration (C(max)) and area under the plasma concentration-time curve over the dosing interval at steady-state (AUC(ss)) of eslicarbazepine (ESL major active

2010 Current medical research and opinion

106. Eslicarbazepine Acetate: A Well-Kept Secret? Full Text available with Trip Pro

Eslicarbazepine Acetate: A Well-Kept Secret? 20126330 2010 06 28 2018 11 13 1535-7511 10 1 2010 Jan Epilepsy currents Epilepsy Curr Eslicarbazepine acetate: a well-kept secret? 7-8 10.1111/j.1535-7511.2009.01337.x Ben-Menachem Elinor E eng Comment Journal Article United States Epilepsy Curr 101135954 1535-7511 Epilepsia. 2009 Mar;50(3):454-63 19243424 2010 2 4 6 0 2010 2 4 6 0 2010 2 4 6 1 ppublish 20126330 10.1111/j.1535-7511.2009.01337.x PMC2812714 Lancet. 2007 Mar 24;369(9566):1000-15

2010 Epilepsy Currents

107. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. (Abstract)

Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. To investigate the efficacy and safety of once-daily eslicarbazepine acetate (ESL) when used as add-on treatment in adults with > or = 4 partial-onset seizures per 4-week despite treatment with 1 to 3 antiepileptic drugs (AEDs).This double-blind, parallel-group, multicenter study consisted of an 8-week observational baseline period, after which patients were randomized to placebo (n=100) or once-daily ESL 400 (...) , blurred vision, and fatigue. The majority of AEs were of mild or moderate severity.Treatment with once-daily eslicarbazepine acetate 800 mg and 1200 mg was more effective than placebo and generally well tolerated in patients with partial-onset seizures refractory to treatment with 1 to 3 concomitant AEDs.Copyright 2010 Elsevier B.V. All rights reserved.

2010 Epilepsy research Controlled trial quality: uncertain

108. Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. (Abstract)

Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. To evaluate the long-term efficacy and safety of once daily eslicarbazepine acetate (ESL) as adjunctive therapy for partial-onset seizures in adults with epilepsy.One-year open-label treatment extension with ESL in patients who completed a placebo-controlled pivotal study (Epilepsia 2009; 50: 454-463). Starting dose was 800 mg once daily

2010 Epilepsia Controlled trial quality: uncertain

109. Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. (Abstract)

Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. The results of two single-blind studies conducted to evaluate the cognitive and psychomotor effects of eslicarbazepine acetate and oxcarbazepine following single and repeated administration in healthy volunteers are reported. The cognitive and psychomotor evaluation consisted of several computerized and paper-and-pencil measures. Eslicarbazepine acetate and oxcarbazepine had similar (...) overall cognitive profiles and did not cause clinically relevant cognitive impairment. The incidence of adverse events was lower with eslicarbazepine acetate than with oxcarbazepine.Copyright 2010. Published by Elsevier Inc.

2010 Epilepsy & behavior : E&B Controlled trial quality: uncertain

110. Brivaracetam - Benefit assessment

of the following drugs: eslicarbazepine or gabapentin or lacosamide or lamotrigine or levetiracetam or oxcarbazepine or pregabalin or topiramate or valproic acid or zonisamide a: Presentation of the appropriate comparator therapy specified by the G-BA. G-BA: Federal Joint Committee The company claimed to have followed the G-BA regarding the ACT, but limited its assessment to a comparison with 2 of the drugs specified by the G-BA (lacosamide and eslicarbazepine). This approach was not followed because all drugs (...) specified by the G-BA are an option for a comprehensive individual antiepileptic adjunctive treatment. Irrespective of this, it was investigated whether, in the studies presented by the company, lacosamide or eslicarbazepine constituted the individually optimized treatment for the patients included in these studies. The assessment was conducted based on patient-relevant outcomes and on the data provided by the company in the dossier. Studies with a minimum duration of the maintenance phase of 12 weeks

2016 Institute for Quality and Efficiency in Healthcare (IQWiG)

111. Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy

, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate or topiramate. If adjunctive treatment is ineffective or not tolerated, the guideline recommends that decisions about treatment options should be made after advice from a tertiary epilepsy specialist. Anti- epileptic drugs that may be considered include eslicarbazepine acetate, lacosamide, phenobarbital, phenytoin, pregabalin, tiagabine, vigabatrin and zonisamide. Prescribers should be aware that not all the drugs mentioned above currently have (...) was considered during the development of The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care (NICE clinical guideline 137). Based on evidence that was available at the time (up to June 2010), the Guideline Development Group found that zonisamide was one of several anti-epileptic drugs that were more costly and less effective than other cost- effective treatment alternatives. The Guideline Development Group concluded that eslicarbazepine acetate

2014 National Institute for Health and Clinical Excellence - Advice

112. Epilepsy in Pregnancy

, phenytoin, phenobarbital, primidone, oxcarbazepine, topiramate and eslicarbazepine) should be counselled about the risk of failure with some hormonal contraceptives. Women should be counselled that the efficacy of oral contraceptives (combined hormonal contraception, progestogen-only pills), transdermal patches, vaginal ring and progestogen-only implants may be affected if they are taking enzyme-inducing AEDs (e.g. carbamazepine, phenytoin, phenobarbital, primidone, oxcarbazepine and eslicarbazepine (...) in the levetiracetam monotherapy group (0.7 per 100; 95% CI 0.19–2.51) than the polytherapy group (5.6 per 100, 95% CI 3.54–8.56). 10 There is insufficient evidence to provide robust estimates of risk of major congenital malformation for other AEDs in monotherapy such as eslicarbazepine, gabapentin, lacosamide, oxcarbazepine, perampanel, pregabalin, topiramate or zonisamide. The risk of recurrence for major congenital malformation was increased (16.8 per 100) in WWE with a previous child with major congenital

2016 Royal College of Obstetricians and Gynaecologists

113. Epilepsies: diagnosis and management

. Other AEDs that may be considered by the tertiary epilepsy specialist are eslicarbazepine acetate [15] , lacosamide, phenobarbital, phenytoin, pregabalin [15] , tiagabine, vigabatrin and zonisamide [15] . Carefully consider the risk–benefit ratio when using vigabatrin because of the risk of an irreversible effect on visual fields. [new [new 2012] 2012] 1.9.4 1.9.4 Pharmacological treatment of newly diagnosed Pharmacological treatment of newly diagnosed gener generalised tonic–clonic alised tonic

2012 National Institute for Health and Clinical Excellence - Clinical Guidelines

114. Partial-onset seizures in epilepsy: zonisamide as monotherapy

effective than other cost-effective treatment alternatives. The Guideline Development Group concluded that eslicarbazepine acetate, lacosamide, pregabalin, tiagabine and zonisamide should be considered only when initial adjunctive therapy options are contraindicated, ineffective or not tolerated. See the introduction for more details. A NICE Pathway on epilepsy brings together all NICE guidance and associated products on epilepsy. Introduction Introduction Epilepsy is a common neurological condition (...) clinical guideline on epilepsy recommends that advice should be sought from a tertiary epilepsy specialist. Anti-epileptic drugs that may be considered are eslicarbazepine acetate, lacosamide, phenobarbital, phenytoin, pregabalin, tiagabine, vigabatrin and zonisamide. The NICE technology appraisal on retigabine for the adjunctive treatment of partial onset seizures in epilepsy (NICE technology appraisal guidance 232) recommends retigabine as an option at this point. Product o Product ov verview erview

2013 National Institute for Health and Clinical Excellence - Advice

116. Contraception - emergency

-inducing drugs or who have taken them within the past 28 days. Table 1 lists some drugs that induce liver enzymes, and may decrease the efficacy of emergency hormonal contraception. Table 1. Drugs that induce liver enzymes. Drug class Drug Antiepileptics Carbamazepine, eslicarbazepine, oxcarbazepine, phenytoin, phenobarbital, primidone, rufinamide, topiramate (weak inducer) Antibiotics Rifampicin (potent inducer), rifabutin Antiretrovirals Protease inhibitors: ritonavir, atazanavir, darunavir

2019 NICE Clinical Knowledge Summaries

117. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and th Full Text available with Trip Pro

-quality studies suggest clobazam, eslicarbazepine, ezogabine, felbamate, GBP, lacosamide, LEV, LTG, oxcarbazepine, perampanel, pregabalin, rufinamide, tiagabine, topiramate, vigabatrin, or ZNS is effective in treating new-onset epilepsy because no high-quality studies exist in adults of various ages. A recent Food and Drug Administration (FDA) strategy allows extrapolation of efficacy across populations; therefore, for focal epilepsy, eslicarbazepine and lacosamide (oral only for pediatric use) as add

2018 EvidenceUpdates

118. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Full Text available with Trip Pro

(Level B): lacosamide, eslicarbazepine, and extended-release topiramate for TRAFE (ezogabine production discontinued); immediate- and extended-release lamotrigine for generalized epilepsy with TR generalized tonic-clonic (GTC) seizures in adults; levetiracetam (add-on therapy) for TR childhood focal epilepsy (TRCFE) (1 month-16 years), TR GTC seizures, and TR juvenile myoclonic epilepsy; clobazam for LGS (add-on therapy); zonisamide for TRCFE (6-17 years); oxcarbazepine for TRCFE (1 month-4 years (...) ). The text presents Level C recommendations. AED selection depends on seizure/syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. This evidence-based assessment informs AED prescription guidelines for TR epilepsy and indicates seizure types and syndromes needing more evidence. A recent Food and Drug Administration (FDA) strategy allows extrapolation of efficacy across populations; therefore, for focal epilepsy, eslicarbazepine and lacosamide (oral only

2018 EvidenceUpdates

119. Influence of dose and antiepileptic comedication on brivaracetam serum concentrations in patients with epilepsy. (Abstract)

used for statistical analysis. GEE analyses showed that BRV trough serum concentrations were significantly lower in patients with strong enzyme-inducing AEDs (carbamazepine, phenytoin, and/or phenobarbital/primidone, -49%), but were not affected by concomitant intake of oxcarbazepine or eslicarbazepine. Age and gender did not have a significant effect. An alternative GEE model analyzing the BRV level-to-dose ratios yielded comparable results. Our results from routine therapeutic drug monitoring

2020 Epilepsia

120. Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? (Abstract)

of acquired epilepsy, a number of medications in clinical use for diverse indications have been shown to have antiepileptogenic or disease-modifying effects, including medications with excellent side effect profiles. These include atorvastatin, ceftriaxone, losartan, isoflurane, N-acetylcysteine, and the antiseizure medications levetiracetam, brivaracetam, topiramate, gabapentin, pregabalin, vigabatrin, and eslicarbazepine acetate. In addition, there are preclinical antiepileptogenic data for anakinra

2020 Epilepsia

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>